Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Payables (2021 - 2025)

Indivior Pharmaceuticals has reported Payables over the past 5 years, most recently at $250.0 million for Q4 2025.

  • Quarterly results put Payables at $250.0 million for Q4 2025, up 15.74% from a year ago — trailing twelve months through Dec 2025 was $250.0 million (up 15.74% YoY), and the annual figure for FY2025 was $250.0 million, up 15.74%.
  • Payables for Q4 2025 was $250.0 million at Indivior Pharmaceuticals, up from $215.0 million in the prior quarter.
  • Over the last five years, Payables for INDV hit a ceiling of $723.0 million in Q4 2021 and a floor of $183.0 million in Q1 2025.
  • Median Payables over the past 5 years was $215.5 million (2024), compared with a mean of $325.1 million.
  • Biggest five-year swings in Payables: tumbled 68.06% in 2023 and later grew 15.74% in 2025.
  • Indivior Pharmaceuticals' Payables stood at $723.0 million in 2021, then fell by 14.25% to $620.0 million in 2022, then tumbled by 68.06% to $198.0 million in 2023, then grew by 9.09% to $216.0 million in 2024, then increased by 15.74% to $250.0 million in 2025.
  • The last three reported values for Payables were $250.0 million (Q4 2025), $215.0 million (Q3 2025), and $196.0 million (Q2 2025) per Business Quant data.